Filing and Business Context
The provided filing is NeuroBo Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2021, filed March 31, 2022. The request metadata identifies “Metavia Inc.”, which does not match the registrant named in the filing. NeuroBo is a clinical-stage biotechnology company with no approved commercial products and four principal programs: ANA001 for COVID-19, NB-01 for painful diabetic neuropathy, NB-02 for neurodegenerative diseases, and Gemcabene for cardiometabolic and potential COVID-19 indications.
Financial Highlights
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No revenue in either period |
| Research and development expense | $6.5 million | $4.5 million | Increase of $2.0 million |
| Acquired in-process R&D | $0 | $17.3 million | Decrease of $17.3 million |
| General and administrative expense | $8.8 million | $7.8 million | Increase of $0.9 million |
| Total operating expenses | $15.3 million | $29.7 million | Decrease of $14.4 million |
| Net loss | $15.3 million | $29.7 million | Loss decreased by $14.4 million |
| Basic and diluted loss per share | $0.66 loss | $1.83 loss | Improved |
| Net cash used in operating activities | $15.1 million | $10.8 million | Use increased by $4.4 million |
| Cash and cash equivalents at year-end | $16.4 million | $10.1 million | Increase of $6.3 million |
| Accumulated deficit | $81.8 million | $66.5 million | Increase of $15.3 million |
The filing does not present product revenue, gross margin, or operating margin because NeuroBo has not commercialized a product. The company had no debt reported other than lease liabilities of $71,000, including $26,000 current and $45,000 long term.
Cash Flow, Capitalization and Liquidity
- Operating cash use was $15.1 million, compared with $10.8 million in 2020.
- Financing activities provided $22.0 million, primarily from $10.0 million of gross proceeds in a January 2021 private placement and approximately $14.0 million in an October 2021 registered direct offering, partly offset by $2.1 million of issuance costs.
- Year-end cash was $16.4 million, while total liabilities were $2.2 million and stockholders’ equity was $14.6 million.
- Shares outstanding increased to 26.7 million at December 31, 2021 from 19.7 million at December 31, 2020. Warrants for approximately 6.9 million shares were outstanding at year-end, creating potential future dilution.
- Management expects existing cash to fund operations into the fourth quarter of 2022 at the then-current level of scientific activity. Cost reductions could potentially extend the operating runway into the first quarter of 2023.
- The auditors included a going-concern explanatory paragraph. Management stated that substantial additional financing is required and that no additional financing commitments were in place at the filing date.
Material Changes Versus 2020
- Net loss declined primarily because 2020 included a $17.3 million noncash acquired in-process R&D charge related to the ANA Therapeutics acquisition.
- Research and development spending increased as clinical trial and manufacturing activity for ANA001 expanded.
- General and administrative expense increased because of higher personnel, public-company, and insurance costs.
- ANA001 remained the lead program in a Phase 2/3 COVID-19 study. The company expected Phase 2 data in the third quarter of 2022 and planned to discuss a potential EUA or 505(b)(2) NDA pathway with the FDA.
- Development of NB-01 on its prior pharmaceutical pathway was discontinued before Phase 3. The company was evaluating orphan-drug and nutraceutical alternatives.
- Work on NB-02’s IND and first human trial was postponed to conserve cash, with potential partnering under consideration.
- Gemcabene’s dyslipidemia program remained on FDA partial clinical hold, and the company shifted attention toward potential COVID-19 applications, including combination use with ANA001.
Outlook, Risks and Unusual Items
- The Phase 2 ANA001 trial was expected to be delayed after clinical sites in Ukraine and Poland were suspended and subsequently terminated following Russia’s invasion of Ukraine.
- ANA001 remained unapproved and dependent on successful clinical results, regulatory review, manufacturing, patient enrollment, and additional financing. The filing does not establish that an EUA or NDA will be obtained.
- Gemcabene carries significant regulatory and commercialization uncertainty. Pfizer may terminate its license if a commercial sale is not achieved by April 16, 2024. The company also has contingent value rights obligations that could transfer 80% of gross consideration for cardiovascular uses and 10% for non-cardiometabolic uses, including COVID-19.
- The company depends on third-party CROs and manufacturers, including Dong-A ST for certain botanical programs, creating execution, supply, quality, and timing risks.
- NeuroBo reported material weaknesses in internal control over financial reporting relating to segregation of duties and logical access to financial systems. Remediation was in progress but not complete at filing.
- On March 18, 2022, Nasdaq notified the company that its stock price did not meet the $1.00 minimum bid requirement. The company had until September 14, 2022 to regain compliance, subject to Nasdaq rules.
- The company had no material legal proceedings identified by management, but it had contractual obligations for leases, cultivation services, licenses, royalties, and potential development milestones. No milestone or royalty liabilities were recorded because payments were not considered probable.
- The company held approximately $16.0 million of cash deposits above federally insured limits at December 31, 2021.
Investor Verification Priorities
- Verify the registrant identity: the source filing is for NeuroBo Pharmaceuticals, Inc. and ticker NRBO, not Metavia Inc.
- Verify current cash, subsequent financings, and the actual operating runway after December 31, 2021.
- Verify the status and results of the ANA001 Phase 2 trial, including the effect of the Ukraine and Poland site closures and any FDA discussions.
- Verify whether Nasdaq listing compliance was restored and whether any reverse split or other capital restructuring occurred.
- Review warrant terms and share dilution, including the approximately 6.9 million warrants outstanding at year-end.
- Assess the going-concern disclosure, funding requirements, and potential dilution or restrictions associated with future financing.
- Review the unresolved material weaknesses in financial controls and subsequent remediation progress.
- Verify the status of Gemcabene’s FDA partial clinical hold, the Pfizer April 2024 commercial-sale requirement, and applicable CVR obligations.